Intralipid (Soya Oil, Purified)

The soybean oil in Intralipid consists of triglycerides that are hydrolyzed by lipases after infusion, releasing free fatty acids and glycerol. These components provide a dense source of energy and supply essential fatty acids (linoleic and α‑linolenic acids) required for cell‑membrane synthesis, hormone production, and other metabolic functions.

The prescribed dose of Intralipid is individualized by the treating clinician based on the patient’s caloric needs, weight, lipid tolerance, and overall parenteral nutrition plan. Dosage calculations typically consider total energy requirements (kcal/kg/day) and the desired proportion of calories supplied by lipids, with adjustments made according to serum triglyceride monitoring.

Safety data for Intralipid in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use is generally reserved for situations where the benefits to the mother outweigh potential risks to the fetus. Breastfeeding mothers should consult their healthcare provider, as lipid emulsions may be transferred into breast milk.

To place an order, submit an enquiry on the Intralipid product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and the necessary import documentation.

Intralipid is a soybean‑oil based emulsion, whereas alternatives such as SMOFlipid or ClinOleic contain mixtures of soybean, medium‑chain triglycerides, olive oil, or fish oil. Compared with pure soybean formulations, mixed‑oil products may offer a more balanced fatty‑acid profile and reduced risk of hypertriglyceridemia, but clinical choice depends on patient‑specific factors, tolerance, and institutional protocols.

Intralipid should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. The emulsion remains stable for up to 24 hours at room temperature after removal from refrigeration, after which any unused portion should be discarded. Always keep the product in its original packaging to maintain sterility.

Intralipid is given as an intravenous infusion, typically through a central venous catheter or a peripheral line capable of handling the emulsion’s viscosity. The infusion rate is calculated by the prescribing clinician and may be administered continuously over 12‑24 hours or as a shorter, controlled infusion, depending on the patient’s nutritional plan and lipid tolerance.

Serious adverse events include anaphylactic or severe hypersensitivity reactions, fat overload syndrome, and pulmonary embolism due to lipid aggregation. Patients with severe hypertriglyceridemia, compromised liver function, or known soy/egg protein allergy are at higher risk. Prompt recognition of symptoms such as respiratory distress, sudden hypotension, or unexplained fever is essential for immediate medical intervention.

Intralipid is contraindicated in individuals with known hypersensitivity to soybean oil, egg phospholipids, or any component of the emulsion. It should also be avoided in patients with severe hypertriglyceridemia, uncontrolled sepsis, or those receiving incompatible intravenous solutions. Clinical judgment is required for patients with hepatic impairment, pancreatitis, or metabolic disorders that affect lipid metabolism.